Pfizer Inc. recalls Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per blister pack, NDC 0049-2340-05; b) 6 table…

Recall date

April 29, 2019

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Recall number

D-1278-2019

FDA classification

Class III

Brand / firm

Pfizer Inc.

Sold / distributed

Nationwide in the USA

Why it was recalled

Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg eletriptan, instead of 40mg, on one side of the carton.

Class III means the product violates regulations but is not likely to cause harm.

What was recalled

Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per blister pack, NDC 0049-2340-05; b) 6 tablets 1 card x six 40 mg tablets per blister pack, NDC 0049-2340-45, Rx Only, Made in Ireland, Distributed by Roerig, Division of Pfizer Inc, NY NY 10017.